首页>
外文期刊>Disease Prevention Daily.
>Researchers from Nanchang University Detail Findings in Kidney Transplants (Population Pharmacokinetic Analysis and Dosing Guidelines for Tacrolimus Co-administration With Wuzhi Capsule In Chinese Renal Transplant Recipients)
【24h】
Researchers from Nanchang University Detail Findings in Kidney Transplants (Population Pharmacokinetic Analysis and Dosing Guidelines for Tacrolimus Co-administration With Wuzhi Capsule In Chinese Renal Transplant Recipients)
2021 MAY 03 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - Current study results on Transplant Medicine - Kidney Transplants have been published. According to news reporting originating in Jiangxi, People's Republic of China, by NewsRx journalists, research stated, "What is known and objectives Tacrolimus (TAC) is a first-line immunosuppressant which is used to prevent transplant rejection after solid organ transplantation (SOT). However, it has a narrow therapeutic index and high individual variability in pharmacokinetics (PK) and pharmacogenomics (PG)." Funders for this research include National Natural Science Foundation of China (NSFC), Wu Jieping Medical Foundation, Jiangxi Provincial Department of Science and Technology. The news reporters obtained a quote from the research from Nanchang University, "It has been reported that the metabolism of TAC can be affected by genetic factors, leading to different rates of metabolism in different subjects. Wuzhi Capsule (WZC) is a commonly used TAC-sparing agent in Chinese SOT to reduce TAC dosing due to its inhibitory effect on TAC metabolism by enzymes of the CYP3A subfamily. The aims of this study were to assess the effect of TAC+WZC co-administration and genetic polymorphism on the pharmacokinetics of TAC, by using a population pharmacokinetic (PPK) model.
展开▼
